Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.83 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.83 |
| ▸ | PPARG | P37231 | 1/20 | 0.83 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.75 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.68 |
| ▸ | TTR | P02766 | 2/20 | 0.68 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.68 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.68 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.68 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.68 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029096 | 0.93 | PTGS2 (1.00) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| Lumiracoxib SCHEMBL4479 | 0.91 | PTGS2 (1.00) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| Lumiracoxib SCHEMBL29475008 | 0.91 | PTGS2 (1.00) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| Lumiracoxib SCHEMBL29377334 | 0.91 | PTGS2 (1.00) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL1032535 | 0.90 | PTGS2 (0.87) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| Lumiracoxib SCHEMBL27680523 | 0.90 | PTGS2 (0.98) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL7633551 | 0.86 | PTGS2 (0.76) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL6036162 | 0.86 | PTGS2 (0.76) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| 5-Hydroxy-Diclofenac SCHEMBL2738864 | 0.86 | CAMK2A (1.00) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL6036626 | 0.86 | PTGS2 (0.82) | PTGS2ABCB11PTGS1NR1I3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | claimed |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | claimed |
| EP-1216226-B1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | claimed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | claimed |
| EP-1007505-B1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | NOVARTIS AG (CH) | 2003-04-16 | — | — | EP | claimed |
| JP-2003510303-A | — | — | 2003-03-18 | — | — | JP | claimed |
| EP-1216226-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | Novartis AG (CH) | 2002-06-26 | — | — | EP | claimed |
| WO-2001023346-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | claimed |
| EP-3693022-A2 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3242688-B1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | REILEY PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. | 2016-07-14 | — | — | US | disclosed |
| WO-2016111834-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | Reiley Pharmaceuticals, Inc. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| US-6451858-B2 | FOR THERAPY OF INFLAMMATION, PYRESIS, PAIN, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, MIGRAINE HEADACHE, CANCER, MELANOMA, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, OSTEOPOROSIS, ASTHMA, LUPUS AND PSORIASIS; SIDE EFFECT REDUCTION | NOVARTIS AG (CH) | 2002-09-17 | — | — | US | disclosed |
| EP-1216226-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | Novartis AG (CH) | 2002-06-26 | — | — | EP | disclosed |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-01-31 | — | — | US | disclosed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | disclosed |
| US-6291523-B1 | SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| WO-2001023346-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200752-A1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | PTGS2, PTGES2, TOP2A | PTGS2 1/4885ABCB11 2015/4885PTGS1 6/4885 |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | HCAR2, CYP2F1, CYP2E1 | PTGS2 5/4885ABCB11 694/4885PTGS1 4/4885 |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ALDH7A1, CYP4F11, CYP2A6 | PTGS2 73/4885ABCB11 296/4885PTGS1 24/4885 |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | ALDH7A1, CYP4F11, CYP2A6 | PTGS2 73/4885ABCB11 296/4885PTGS1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.